Chi-Med loss widens on R&D costs but revenues strong
This article was originally published in Scrip
Executive Summary
Hutchison China MediTech (Chi-Med)'s net loss rose to $17.8 million last year from $17.2 million in calendar 2007, affected by higher R&D spending. Nevertheless, the company said the fundamentals of its business remained strong, with the China Healthcare division logging particularly good growth.